|
ES2502490T3
(es)
*
|
2003-02-26 |
2014-10-03 |
Sugen, Inc. |
Compuestos aminoheteroarílicos como inhibidores de proteín quinasas
|
|
EP1720574A4
(en)
*
|
2004-02-23 |
2009-09-09 |
Sugen Inc |
METHOD FOR THE TREATMENT OF ABNORMAL CELL GROWTH WITH C-MET AND TOR HEMMERN
|
|
NZ547517A
(en)
|
2004-02-27 |
2009-04-30 |
Eisai R&D Man Co Ltd |
Novel pyridine and pyrimidine derivatives for hepatocyte growth and tumour inihibition
|
|
BRPI0508230A
(pt)
*
|
2004-03-30 |
2007-07-17 |
Chiron Corp |
derivados de tiofeno substituìdo como agentes anti-cáncer
|
|
ATE454372T1
(de)
|
2004-04-01 |
2010-01-15 |
Lilly Co Eli |
Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
|
|
US8008301B2
(en)
|
2004-04-01 |
2011-08-30 |
Eli Lilly And Company |
Histamine H3 receptor agents, preparation and therapeutic uses
|
|
ES2534605T3
(es)
*
|
2004-08-23 |
2015-04-24 |
Eli Lilly And Company |
Agentes receptores de la histamina H3, preparación y usos terapéuticos
|
|
AP2332A
(en)
*
|
2004-08-26 |
2011-12-05 |
Pfizer |
Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors.
|
|
WO2006021886A1
(en)
*
|
2004-08-26 |
2006-03-02 |
Pfizer Inc. |
Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
|
|
JP2008510791A
(ja)
*
|
2004-08-26 |
2008-04-10 |
ファイザー・インク |
プロテインチロシンキナーゼ阻害薬中間体の調製のためのエナンチオ選択性生体内変換
|
|
NZ552866A
(en)
*
|
2004-08-26 |
2010-06-25 |
Pfizer |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
|
GT200600042A
(es)
*
|
2005-02-10 |
2006-09-27 |
Aventis Pharma Inc |
Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
|
|
AU2006218404A1
(en)
*
|
2005-03-03 |
2006-09-08 |
Sirtris Pharmaceuticals, Inc. |
N-phenyl benzamide derivatives as sirtuin modulators
|
|
AU2006247482A1
(en)
*
|
2005-05-13 |
2006-11-23 |
Lexicon Pharmaceuticals, Inc. |
Multicyclic compounds and methods of their use
|
|
US8093401B2
(en)
*
|
2005-08-04 |
2012-01-10 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
|
US8088928B2
(en)
*
|
2005-08-04 |
2012-01-03 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
|
US7855289B2
(en)
*
|
2005-08-04 |
2010-12-21 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
|
CA2618370A1
(en)
*
|
2005-08-04 |
2007-02-15 |
Sirtris Pharmaceuticals, Inc. |
Oxazolopyridine derivatives as sirtuin modulators
|
|
KR100950737B1
(ko)
*
|
2005-08-24 |
2010-03-31 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
신규 피리딘 유도체 및 피리미딘 유도체(3)
|
|
PT1959955E
(pt)
*
|
2005-12-05 |
2011-01-04 |
Pfizer Prod Inc |
Método para tratar o crescimento celular anómalo
|
|
AU2006323025B2
(en)
*
|
2005-12-05 |
2012-07-05 |
Pfizer Products Inc. |
Polymorphs of a c-Met/HGFR inhibitor
|
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
|
JP2009529047A
(ja)
|
2006-03-07 |
2009-08-13 |
アレイ バイオファーマ、インコーポレイテッド |
ヘテロ二環系ピラゾール化合物およびその使用
|
|
ATE453635T1
(de)
*
|
2006-03-22 |
2010-01-15 |
Vertex Pharma |
C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
|
|
US8168383B2
(en)
|
2006-04-14 |
2012-05-01 |
Cell Signaling Technology, Inc. |
Gene defects and mutant ALK kinase in human solid tumors
|
|
ES2637592T3
(es)
|
2006-04-14 |
2017-10-13 |
Cell Signaling Technology, Inc. |
Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
|
|
US7601716B2
(en)
|
2006-05-01 |
2009-10-13 |
Cephalon, Inc. |
Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
|
|
EP2338488A1
(en)
*
|
2006-05-26 |
2011-06-29 |
Bayer HealthCare, LLC |
Drug combinations with substituted diaryl ureas for the treatment of cancer
|
|
CA2655128A1
(en)
*
|
2006-06-08 |
2007-12-21 |
Array Biopharma Inc. |
Quinoline compounds and methods of use
|
|
US7683060B2
(en)
|
2006-08-07 |
2010-03-23 |
Incyte Corporation |
Triazolotriazines as kinase inhibitors
|
|
ES2375284T3
(es)
*
|
2006-08-23 |
2012-02-28 |
Eisai R&D Management Co., Ltd. |
Sal de un derivado de fenoxipiridina, o cristal de la misma, y procedimiento de producción de la misma.
|
|
US7790885B2
(en)
*
|
2006-08-31 |
2010-09-07 |
Eisai R&D Management Co., Ltd. |
Process for preparing phenoxypyridine derivatives
|
|
WO2008042867A2
(en)
*
|
2006-09-29 |
2008-04-10 |
Emiliem Inc. |
Modulators of multiple kinases
|
|
AU2007309427B2
(en)
|
2006-10-23 |
2013-02-28 |
Cephalon, Inc. |
Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
|
|
GB0621607D0
(en)
*
|
2006-10-31 |
2006-12-06 |
Chroma Therapeutics Ltd |
Inhibitors of c-Met
|
|
MY188335A
(en)
|
2006-11-22 |
2021-11-30 |
Incyte Holdings Corp |
Imidazotriazines and imidazopyrimidines as kinase inhibitors
|
|
NZ577611A
(en)
|
2006-12-14 |
2012-01-12 |
Bayer Schering Pharma Ag |
Dihydropyridine derivatives useful as protein kinase inhibitors
|
|
ES2531002T3
(es)
*
|
2007-01-19 |
2015-03-09 |
Xcovery Inc |
Compuestos inhibidores de quinasa
|
|
JPWO2008087736A1
(ja)
*
|
2007-01-19 |
2010-05-06 |
宇部興産株式会社 |
アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法
|
|
JP5926487B2
(ja)
*
|
2007-04-13 |
2016-05-25 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
ＥｒｂＢ療法に耐性である癌を治療するための方法
|
|
PL2134685T3
(pl)
|
2007-04-16 |
2016-02-29 |
Abbvie Inc |
Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1
|
|
US8263585B2
(en)
|
2007-05-04 |
2012-09-11 |
Novartis Ag |
Organic compounds
|
|
CL2008001822A1
(es)
*
|
2007-06-20 |
2009-03-13 |
Sirtris Pharmaceuticals Inc |
Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
|
|
CA2695004C
(en)
|
2007-07-17 |
2016-01-19 |
Plexxikon, Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
WO2009013348A2
(en)
*
|
2007-07-26 |
2009-01-29 |
Novartis Ag |
Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
|
|
US8748143B2
(en)
|
2007-09-13 |
2014-06-10 |
Codexis, Inc. |
Ketoreductase polypeptides for the reduction of acetophenones
|
|
AU2008317107B2
(en)
*
|
2007-10-23 |
2013-09-12 |
Allergan, Inc. |
Therapeutic substituted lactams
|
|
BRPI0819093A2
(pt)
*
|
2007-11-01 |
2017-05-02 |
Sirtris Pharmaceuticals Inc |
compostos moduladores de sirtuína
|
|
AU2008325148A1
(en)
*
|
2007-11-08 |
2009-05-14 |
Sirtris Pharmaceuticals, Inc. |
Solubilized thiazolopyridines
|
|
JP2009132660A
(ja)
|
2007-11-30 |
2009-06-18 |
Eisai R & D Management Co Ltd |
食道癌治療用組成物
|
|
WO2009073224A1
(en)
*
|
2007-12-07 |
2009-06-11 |
Ambit Biosciences Corp. |
Methods of treating certain diseases using pyrimidine derivatives
|
|
JP2009203226A
(ja)
*
|
2008-01-31 |
2009-09-10 |
Eisai R & D Management Co Ltd |
ピリジン誘導体およびピリミジン誘導体を含有するレセプターチロシンキナーゼ阻害剤
|
|
WO2009096198A1
(ja)
*
|
2008-02-01 |
2009-08-06 |
Pharma Ip Limited Liability Intermediary Corporations |
新規ビアリール誘導体
|
|
JP2011511005A
(ja)
*
|
2008-02-04 |
2011-04-07 |
オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド |
２−アミノピリジン系キナーゼ阻害薬
|
|
AR070317A1
(es)
|
2008-02-06 |
2010-03-31 |
Osi Pharm Inc |
Furo (3,2-c) piridina y tieno (3,2-c) piridinas
|
|
JPWO2009104520A1
(ja)
*
|
2008-02-18 |
2011-06-23 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
フェノキシピリジン誘導体の製造方法（２）
|
|
US20110092452A1
(en)
*
|
2008-03-05 |
2011-04-21 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
|
US8268834B2
(en)
*
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
|
FR2928923B1
(fr)
|
2008-03-21 |
2010-04-23 |
Sanofi Aventis |
Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
|
|
FR2928924B1
(fr)
|
2008-03-21 |
2010-04-23 |
Sanofi Aventis |
Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
|
|
FR2928922B1
(fr)
|
2008-03-21 |
2010-04-23 |
Sanofi Aventis |
Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
|
|
US20110039860A1
(en)
*
|
2008-05-07 |
2011-02-17 |
Cangming Yang |
Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
|
|
BRPI0912882A2
(pt)
|
2008-05-21 |
2017-05-16 |
Incyte Corp |
sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos
|
|
ES2551899T3
(es)
|
2008-06-19 |
2015-11-24 |
Xcovery Holding Company Llc |
Compuestos de piridazina carboxamida sustituidos como compuestos inhibidores de cinasas
|
|
CN102137939A
(zh)
*
|
2008-08-29 |
2011-07-27 |
霍夫曼-拉罗奇有限公司 |
不依赖vegf的肿瘤的诊断和治疗
|
|
WO2010046780A2
(en)
*
|
2008-10-22 |
2010-04-29 |
Institut Pasteur Korea |
Anti viral compounds
|
|
AT507187B1
(de)
|
2008-10-23 |
2010-03-15 |
Helmut Dr Buchberger |
Inhalator
|
|
EP2356116A1
(en)
|
2008-11-20 |
2011-08-17 |
OSI Pharmaceuticals, Inc. |
Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
|
|
US8367679B2
(en)
*
|
2008-12-09 |
2013-02-05 |
Merck Sharp & Dohme Corp. |
Biaryl carboxamides
|
|
UA104447C2
(uk)
|
2008-12-19 |
2014-02-10 |
Сіртріз Фармасьютікалз, Інк. |
Тіазолопіридинові сполуки, що модулюють сиртуїн
|
|
SG172248A1
(en)
|
2008-12-19 |
2011-07-28 |
Vertex Pharma |
Pyrazine derivatives useful as inhibitors of atr kinase
|
|
JP2012102018A
(ja)
*
|
2009-03-03 |
2012-05-31 |
Astellas Pharma Inc |
アミド化合物
|
|
TW201100441A
(en)
*
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
|
DE102009056886A1
(de)
|
2009-12-03 |
2011-06-09 |
Bayer Schering Pharma Aktiengesellschaft |
cMet-Inhibitoren zur Behandlung der Endometriose
|
|
JP5714030B2
(ja)
|
2010-02-03 |
2015-05-07 |
インサイト コーポレーションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン
|
|
JP2013525476A
(ja)
*
|
2010-05-04 |
2013-06-20 |
ファイザー・インク |
Ａｌｋ阻害剤としての複素環式誘導体
|
|
EP2569287B1
(en)
|
2010-05-12 |
2014-07-09 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
JP2013529200A
(ja)
*
|
2010-05-12 |
2013-07-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｒキナーゼ阻害剤として有用な化合物
|
|
MX2012013081A
(es)
|
2010-05-12 |
2013-05-09 |
Vertex Pharma |
Compuestos utiles como inhibidores de cinasa atr.
|
|
EP2569315A1
(en)
|
2010-05-14 |
2013-03-20 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
AR081039A1
(es)
|
2010-05-14 |
2012-05-30 |
Osi Pharmaceuticals Llc |
Inhibidores biciclicos fusionados de quinasa
|
|
US10420665B2
(en)
|
2010-06-13 |
2019-09-24 |
W. L. Gore & Associates, Inc. |
Intragastric device for treating obesity
|
|
US8628554B2
(en)
|
2010-06-13 |
2014-01-14 |
Virender K. Sharma |
Intragastric device for treating obesity
|
|
US9526648B2
(en)
|
2010-06-13 |
2016-12-27 |
Synerz Medical, Inc. |
Intragastric device for treating obesity
|
|
US10010439B2
(en)
|
2010-06-13 |
2018-07-03 |
Synerz Medical, Inc. |
Intragastric device for treating obesity
|
|
BR112012032462A2
(pt)
|
2010-06-25 |
2016-11-08 |
Eisai R&D Man Co Ltd |
agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
|
|
US9120752B2
(en)
|
2010-07-16 |
2015-09-01 |
Purdue Pharma, L.P. |
Pyridine compounds as sodium channel blockers
|
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
|
CN103298806B
(zh)
|
2010-10-08 |
2015-03-18 |
贝达药业股份有限公司 |
取代的哒嗪羧酰胺化合物
|
|
EP2646448B1
(en)
|
2010-11-29 |
2017-08-30 |
OSI Pharmaceuticals, LLC |
Macrocyclic kinase inhibitors
|
|
GB201021103D0
(en)
*
|
2010-12-13 |
2011-01-26 |
Univ Leuven Kath |
New compounds for the treatment of neurodegenerative diseases
|
|
US8752545B2
(en)
|
2011-02-11 |
2014-06-17 |
Batmark Limited |
Inhaler component
|
|
WO2012116050A2
(en)
*
|
2011-02-24 |
2012-08-30 |
Eternity Bioscience Inc. |
Phosphorus containing compounds as protein kinase inhibitors
|
|
US9145390B2
(en)
|
2011-03-03 |
2015-09-29 |
Concert Pharmaceuticals, Inc. |
Derivatives of pyrazole-substituted amino-heteroaryl compounds
|
|
JO3438B1
(ar)
|
2011-04-13 |
2019-10-20 |
Epizyme Inc |
مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
|
|
WO2012152741A1
(de)
|
2011-05-10 |
2012-11-15 |
Bayer Intellectual Property Gmbh |
Bicyclische (thio)carbonylamidine
|
|
US20140088114A1
(en)
|
2011-05-16 |
2014-03-27 |
OSI Pharmaceuticals ,LLC |
Fused bicyclic kinase inhibitors
|
|
US9309250B2
(en)
|
2011-06-22 |
2016-04-12 |
Vertex Pharmaceuticals Incorporated |
Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
|
|
WO2013013308A1
(en)
*
|
2011-07-27 |
2013-01-31 |
Beta Pharma Canada Inc. |
Spirocyclic molecules as protein kinase inhibitors
|
|
EP2739284A1
(en)
|
2011-08-02 |
2014-06-11 |
Pfizer Inc |
Crizotinib for use in the treatment of cancer
|
|
SG10201602515QA
(en)
|
2011-09-30 |
2016-05-30 |
Vertex Pharma |
Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
|
|
PT2940017T
(pt)
|
2011-09-30 |
2019-10-31 |
Vertex Pharma |
Processos para a produção de compostos úteis como inibidores de atr quinase
|
|
HUE034118T2
(en)
|
2012-03-06 |
2018-01-29 |
Pfizer |
Macrocyclic derivatives for the treatment of proliferative diseases
|
|
WO2013136170A1
(en)
|
2012-03-16 |
2013-09-19 |
Purdue Pharma L.P. |
Substituted pyridines as sodium channel blockers
|
|
NZ700580A
(en)
|
2012-04-05 |
2016-07-29 |
Vertex Pharma |
Compounds useful as inhibitors of atr kinase and combination therapies thereof
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
NZ729643A
(en)
|
2012-04-13 |
2018-02-23 |
Epizyme Inc |
Combination therapy for treating cancer
|
|
CN103387535B
(zh)
*
|
2012-05-10 |
2016-06-01 |
广东东阳光药业有限公司 |
取代的炔基吡啶化合物及其使用方法和用途
|
|
WO2013177092A1
(en)
*
|
2012-05-23 |
2013-11-28 |
Sunshine Lake Pharma Co., Ltd. |
Substituted alkynyl pyridine compounds and methods of use
|
|
EP2872161B1
(en)
|
2012-06-26 |
2020-12-16 |
Del Mar Pharmaceuticals |
Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
|
|
GB201211310D0
(en)
|
2012-06-26 |
2012-08-08 |
Chroma Therapeutics Ltd |
CSF-1R kinase inhibitors
|
|
CA2881559C
(en)
|
2012-09-24 |
2020-08-04 |
Ventana Medical Systems, Inc. |
Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (alk) as a marker
|
|
WO2014055756A1
(en)
|
2012-10-04 |
2014-04-10 |
Vertex Pharmaceuticals Incorporated |
Method for measuring atr inhibition mediated increases in dna damage
|
|
WO2014081816A1
(en)
*
|
2012-11-21 |
2014-05-30 |
Concert Pharmaceuticals, Inc. |
Fluoro-derivatives of pyrazole-substituted amino-heteroaryl compounds
|
|
FI4190786T3
(fi)
|
2012-12-07 |
2025-05-23 |
Vertex Pharma |
Atr-kinaasin estäjinä käyttökelpoisia yhdisteitä
|
|
US9714252B2
(en)
|
2012-12-20 |
2017-07-25 |
Purdue Pharma L.P. |
Cyclic sulfonamides as sodium channel blockers
|
|
CN104755463A
(zh)
|
2012-12-21 |
2015-07-01 |
卫材R&D管理有限公司 |
非晶态形式的喹啉衍生物及其生产方法
|
|
RU2671212C2
(ru)
*
|
2013-02-02 |
2018-10-30 |
Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд |
Замещенный 2-аминопиридин в качестве ингибитора протеинкиназы
|
|
EP2970286A1
(en)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Inc. |
Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
|
|
AU2014251038A1
(en)
|
2013-04-08 |
2015-11-26 |
Dennis M. Brown |
Therapeutic benefit of suboptimally administered chemical compounds
|
|
JP6411379B2
(ja)
|
2013-05-14 |
2018-10-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
|
|
WO2015034729A1
(en)
*
|
2013-09-05 |
2015-03-12 |
Calitor Sciences, Llc |
Substituted pyridine compounds and methods of use
|
|
US20160214961A1
(en)
*
|
2013-09-10 |
2016-07-28 |
Shilpa Medicare Limited |
Novel salts of crizotinib and their preparation
|
|
RU2550346C2
(ru)
|
2013-09-26 |
2015-05-10 |
Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" |
Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
|
|
CA2923533C
(en)
|
2013-09-30 |
2019-08-06 |
Korea Research Institute Of Chemical Technology |
Triazolopyrazine derivatives and uses thereof
|
|
WO2015069922A2
(en)
|
2013-11-06 |
2015-05-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
|
EP3077397B1
(en)
|
2013-12-06 |
2019-09-18 |
Vertex Pharmaceuticals Inc. |
2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
|
|
CA2934251C
(en)
|
2013-12-20 |
2024-01-02 |
3-V Biosciences, Inc. |
A combination of heterocyclic modulators of lipid synthesis and chemotherapeutic drugs in treatment of cancer
|
|
CN103755627B
(zh)
*
|
2014-01-09 |
2016-02-17 |
定陶县友帮化工有限公司 |
2-氨基-3-羟基-5-氯吡啶的合成方法
|
|
US10231965B2
(en)
|
2014-02-20 |
2019-03-19 |
Ignyta, Inc. |
Molecules for administration to ROS1 mutant cancer cells
|
|
JP2017516458A
(ja)
|
2014-03-24 |
2017-06-22 |
ジェネンテック， インコーポレイテッド |
ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
|
|
US10730866B2
(en)
|
2014-04-07 |
2020-08-04 |
Purdue Pharma L.P. |
Indole derivatives and use thereof
|
|
EP3137074B1
(en)
*
|
2014-04-29 |
2020-08-05 |
Emory University |
Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
|
|
WO2015172747A1
(en)
*
|
2014-05-16 |
2015-11-19 |
Zhaoyin Wang |
Spirocyclic molecules as mth1 inhibitors
|
|
HRP20200186T1
(hr)
|
2014-06-05 |
2020-05-29 |
Vertex Pharmaceuticals Inc. |
Radioaktivno obilježeni derivati 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-karboksamid spojeva koji se koriste kao inhibitori atr kinaze, priprava navedenih spojeva i njihovi različiti čvrsti oblici
|
|
JP6936007B2
(ja)
|
2014-06-17 |
2021-09-15 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法
|
|
WO2016019909A1
(zh)
*
|
2014-08-07 |
2016-02-11 |
江苏豪森药业股份有限公司 |
一种抗癌化合物的新晶型及其制备方法和用途
|
|
CN107108581B
(zh)
|
2014-08-21 |
2020-06-23 |
百时美施贵宝公司 |
作为强效rock抑制剂的回接苯甲酰胺衍生物
|
|
DK3524595T3
(da)
|
2014-08-28 |
2022-09-19 |
Eisai R&D Man Co Ltd |
Quinolinderivat af høj renhed og fremgangsmåde til fremstilling deraf
|
|
AU2015333738B2
(en)
*
|
2014-10-13 |
2020-03-26 |
Atrin Pharmaceuticals LLC |
Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors
|
|
GB2535427A
(en)
|
2014-11-07 |
2016-08-24 |
Nicoventures Holdings Ltd |
Solution
|
|
UY36391A
(es)
*
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
|
|
WO2016073847A2
(en)
*
|
2014-11-07 |
2016-05-12 |
The Regents Of The University Of Michigan |
Inhibitors of myocardin-related transcription factor and serum response factor (mrtf/srf)-mediated gene transcription and methods for use of the same
|
|
WO2016089760A1
(en)
|
2014-12-02 |
2016-06-09 |
Ignyta, Inc. |
Combinations for the treatment of neuroblastoma
|
|
JP6852848B2
(ja)
|
2015-01-13 |
2021-03-31 |
国立大学法人京都大学 |
筋萎縮性側索硬化症の予防及び／又は治療剤
|
|
MA41598A
(fr)
*
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
|
DK3263106T3
(da)
|
2015-02-25 |
2024-01-08 |
Eisai R&D Man Co Ltd |
Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
|
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
|
EP3307725A1
(en)
|
2015-06-11 |
2018-04-18 |
Basilea Pharmaceutica International AG |
Efflux-pump inhibitors and therapeutic uses thereof
|
|
US11369623B2
(en)
|
2015-06-16 |
2022-06-28 |
Prism Pharma Co., Ltd. |
Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
|
|
US10405627B2
(en)
*
|
2015-07-14 |
2019-09-10 |
Michael Charles Boland, III |
Luggage with fold out table
|
|
MX381976B
(es)
|
2015-08-20 |
2025-03-13 |
Eisai R&D Man Co Ltd |
Agente terapéutico contra tumores.
|
|
EP3355926B1
(en)
|
2015-09-30 |
2025-12-24 |
Vertex Pharmaceuticals Inc. |
Combination of dna damaging agents and atr inhibitors for use in a method for treating cancer using
|
|
GB2542838B
(en)
|
2015-10-01 |
2022-01-12 |
Nicoventures Trading Ltd |
Aerosol provision system
|
|
CA3008663A1
(en)
|
2015-12-18 |
2017-06-22 |
Ignyta, Inc. |
Combinations of a selective tyrosine kinase inhibitor (tki) with a mek or erk inhibitor for the treatment of cancer
|
|
WO2017161004A1
(en)
|
2016-03-15 |
2017-09-21 |
University Of South Florida |
PKCδ INHIBITOR FORMULATIONS AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS
|
|
US10301324B2
(en)
|
2016-04-12 |
2019-05-28 |
Atrin Pharmaceuticals LLC |
Ataxia telengiectasia and rad3-related (ATR) inhibitors and methods of their use
|
|
US10779980B2
(en)
|
2016-04-27 |
2020-09-22 |
Synerz Medical, Inc. |
Intragastric device for treating obesity
|
|
US10933068B2
(en)
*
|
2016-05-26 |
2021-03-02 |
Sonic Master Limited |
Modulators of DUX4 for regulation of muscle function
|
|
TWI646094B
(zh)
|
2016-06-01 |
2019-01-01 |
大陸商貝達藥業股份有限公司 |
Crystal form of inhibitory protein kinase active compound and application thereof
|
|
US11046683B2
(en)
|
2016-12-15 |
2021-06-29 |
Ono Pharmaceutical Co., Ltd. |
Activator of TREK (TWIK RElated K+ channels) channels
|
|
CN106866627B
(zh)
*
|
2017-01-24 |
2021-09-14 |
南方医科大学 |
3-(1-(氨基吡啶氧基)乙基)苯甲酰胺衍生物及其合成方法和应用
|
|
WO2018147275A1
(ja)
|
2017-02-08 |
2018-08-16 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療用医薬組成物
|
|
CA3061888A1
(en)
|
2017-05-16 |
2018-11-22 |
Eisai R&D Management Co., Ltd. |
Treatment of hepatocellular carcinoma
|
|
AU2018302179A1
(en)
|
2017-07-18 |
2020-02-13 |
Nuvation Bio Inc. |
Heterocyclic compounds as adenosine antagonists
|
|
BR112020000962A2
(pt)
|
2017-07-18 |
2020-07-14 |
Nuvation Bio Inc. |
compostos de 1,8-naftiridinona e usos dos mesmos
|
|
IL271759B2
(en)
|
2017-07-19 |
2024-01-01 |
Ignyta Inc |
Pharmaceutical preparations that include anthraxtinib
|
|
CN111225662B
(zh)
|
2017-10-17 |
2022-11-22 |
伊尼塔公司 |
药物组合物和剂型
|
|
CN107794282B
(zh)
*
|
2017-11-20 |
2020-12-25 |
浙江工业大学 |
一种克唑替尼手性中间体的制备方法及菌株
|
|
WO2019154665A1
(en)
*
|
2018-02-07 |
2019-08-15 |
Basf Se |
New pyridine carboxamides
|
|
KR102556742B1
(ko)
|
2018-03-15 |
2023-07-18 |
푸지안 하이시 파마슈티칼스 컴퍼니 리미티드 |
키나제 억제제로서의 헤테로아릴 화합물
|
|
CN110372664A
(zh)
*
|
2018-04-13 |
2019-10-25 |
华东理工大学 |
选择性jak2抑制剂及其应用
|
|
CN110396087A
(zh)
*
|
2018-04-25 |
2019-11-01 |
珠海宇繁生物科技有限责任公司 |
Hpk1激酶抑制剂、制备方法及其应用
|
|
WO2019206049A1
(en)
*
|
2018-04-25 |
2019-10-31 |
Zhuhai Yufan Biotechnologies Co., Ltd |
Hpk1 inhibitors, preparation method and application thereof
|
|
CN108947895B
(zh)
*
|
2018-08-22 |
2021-09-24 |
肇庆中彩机电技术研发有限公司 |
一种抗癌活性的化合物
|
|
CN113631167A
(zh)
*
|
2019-01-18 |
2021-11-09 |
诺维逊生物股份有限公司 |
作为腺苷拮抗剂的杂环化合物
|
|
KR20210116550A
(ko)
|
2019-01-18 |
2021-09-27 |
누베이션 바이오 인크. |
아데노신 길항제로서의 헤테로시클릭 화합물
|
|
WO2020150676A1
(en)
|
2019-01-18 |
2020-07-23 |
Nuvation Bio Inc. |
1,8-naphthyridinone compounds and uses thereof
|
|
WO2020191208A1
(en)
|
2019-03-20 |
2020-09-24 |
Emory University |
Prostaglandin receptor ep2 antagonists, derivatives, and uses related thereto
|
|
KR20220004206A
(ko)
|
2019-05-14 |
2022-01-11 |
텔리진 엘티디. |
키네이스 억제제로 유용한 치환된 거대고리화합물
|
|
KR102426921B1
(ko)
|
2019-09-24 |
2022-07-29 |
주식회사 이노보테라퓨틱스 |
헤테로아릴아미도피리딘올 유도체 및 이를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약학적 조성물
|
|
CN112552293A
(zh)
*
|
2019-09-25 |
2021-03-26 |
珠海宇繁生物科技有限责任公司 |
一种protac小分子化合物及其应用
|
|
KR102344185B1
(ko)
*
|
2020-02-26 |
2021-12-27 |
계명대학교 산학협력단 |
신규한 Pim 키나아제 억제제 및 이의 용도
|
|
CN113493437B
(zh)
*
|
2020-04-03 |
2022-07-26 |
中国药科大学 |
含苯并咪唑结构的化合物及其制备方法和用途
|
|
WO2021196655A1
(zh)
*
|
2020-04-03 |
2021-10-07 |
中国药科大学 |
含苯并咪唑结构的化合物及其制备方法与用途
|
|
WO2023086671A1
(en)
*
|
2021-11-15 |
2023-05-19 |
The Broad Institute, Inc. |
Compounds, compositions, and methods for inducing antimicrobial intracellular activity and for preventing and treating microbial infections
|
|
AU2023304031A1
(en)
|
2022-07-04 |
2025-02-06 |
Chugai Seiyaku Kabushiki Kaisha |
Combination drug
|
|
KR20250055574A
(ko)
|
2022-08-30 |
2025-04-24 |
추가이 세이야쿠 가부시키가이샤 |
병용 의약
|